Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease.
The concept of DVM may also help direct which patients may benefit most from stem cell therapy. As the stage of HF that may be considered too late for stem cell therapy is unclear, the presence of DVM may help guide the identification of those patients with the most potential to benefit.
The potential of any therapy, including stem cells, to improve outcomes in ICM or NICM is related not only to its effects on restoring function to DVM, but also to its capacity to improve processes that contribute to A persistent inflammatory state can contribute directly not only to the development of DVM and adverse LV remodeling (10) , but also to increased reactive oxygen species, apoptosis, fibrosis, and microvascular dysfunction, which further exacerbate its effects on DVM and adverse LV remodeling (11) (12) (13) (14) (Central Illustration). It has long been established that inflammation plays a critical role in progression of the arterial wall component of atherosclerotic heart disease (15 However, these 2 trials involved very few patients (10 randomized patients in SCIPIO, 25 in CADUCEUS).
(Note: an "Expression of Concern" was issued by The Lancet [63] relating to the SCIPIO paper, and a critical paper authored by the senior investigator of the laboratory responsible for the stem cell aspect of this study was retracted [64, 65] .) Pre-clinical data pub- Table 1) . This may be a critically important change in stem cell therapeutic strategy that could lead to clinical benefit. The field of stem cell research in HF is extremely active and robust ( Table 1) . Studies are assessing various cell types of either autologous or allogeneic origin and various delivery routes. Thus, despite the remaining issues, we believe that the outcomes data and mechanistic knowledge accumulated from the many pre-clinical and clinical studies performed to date, and the knowledge we will accumulate from studies in progress, have the potential to provide insights that will eventually lead stem cell therapeutics to become a highly successful strategy in improving outcomes in patients with HF. 
